Clinical Trial Update: A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study of BL-M07D1 in HER2-expressing recurrent or metastatic gynecologic cancers is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• BL-M07D1

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Gynecological Malignancies | Phase 1, Phase 2 | Status: RECRUITING